Skip Navigation



Europace Advance Access published online on February 14, 2006
Europace, doi:10.1093/europace/euj042
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
8/3/157    most recent
euj042v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Goette, A.
Right arrow Articles by Auricchio, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goette, A.
Right arrow Articles by Auricchio, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved
Received May 7, 2004
Accepted October 18, 2005

Article

Cardiac uptake of progenitor cells in patients with moderate-to-severe left ventricular failure scheduled for cardiac resynchronization therapy

Andreas Goette 1 *, Kathleen Jentsch-Ullrich 2, Matthias Hammwöhner 1, Silke Trautmann 1, Astrid Franke 2, Helmut U. Klein 1, and Angelo Auricchio 1

1 Division of Cardiology, University Hospital Magdeburg, Leipziger Street 44, 39120 Magdeburg, Germany
2 Division of Hematology/Oncology, University Hospital Magdeburg, Magdeburg, Germany

* To whom correspondence should be addressed.
Andreas Goette, E-mail: andreas.goette{at}medizin.uni-magdeburg.de


  Abstract

Aims Injury to the heart causes haematopoietic and endothelial progenitor cells (PCs) to migrate to the site of damage and to undergo PC differentiation, which may contribute to angiogenesis and myocardial tissue repair. We sought to determine the cardiac uptake of PC in patients with moderate-to-severe congestive heart failure (CHF) scheduled for cardiac resynchronization therapy.

Methods and results A total of 28 patients was included in the study. Fourteen patients had moderate-to-severe CHF with a mean left ventricular ejection fraction (LVEF) of 20 ± 9%. The remaining patients had a normal LVEF and served as controls. PCs (CD34+ and CD34+/CD117+) were quantified using a fluorescence-activated cell sorter. In CHF patients, PCs were determined from whole blood samples taken from the aorta, the coronary sinus (CS), and the superior vena cava (SVC) during right and left heart catheterization. Cardiac PC uptake was determined as the difference in PC levels between the aorta and the CS. Differences in CD34+PC counts ({Delta}0.11 ± 0.98 x 103 mL - 1) and relative amount of CD34+/CD117+PC ({Delta}0.08 ± 0.31%) between the aorta and the CS were not significant. PC levels were comparable between the SVC, CS, and aorta. CD34+ and PC levels did not correlate with New York Heart Association class (r2 = 0.22), LVEF (r2 = 0.01), LV diameter (r2 = 0.05), QRS complex duration (r2 = 0.1), or maximal O2 uptake during exercise (r2 = 0.08). There was no difference between patients with ischaemic cardiomyopathy (ICM) and non-ICM. Systemic PC levels were not different compared with age-matched controls without LV failure (CD34+: 4.61 ± 1.83 x 103 mL - 1 vs. control: 5.25 ± 1.67 x 103 mL - 1; P = n.s.).

Conclusion Moderate-to-severe chronic CHF is not associated with elevated PC levels in the systemic circulation. A measurable cardiac uptake of CD34+ and CD34+/CD117+PC cannot be demonstrated by FACS analysis in this cohort of patients.

Keywords: Blood; Cardiac catherization; Heart failure; Progenitor cells.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.